HRTS
Exchange-traded product on NASDAQ (US)
- Type
- Exchange-traded product
- Share class
- —
- Status
- listed
- ISIN
- —
- Currency
- —
- Represents the company
- No
Holdings as of Aug 31, 2026
The full portfolio as of the quarter end Aug 31, 2026, from the fund's report to the SEC (Form N-PORT, filed Oct 30, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of May 31, 2026.
46 lines, 43 linked, weights sum to 99.92% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | LLY US5324571083 | Equity | 5,343 | −70 | 11.11% | $ 6.18M |
| Thermo Fisher Scientific Inc | TMO US8835561023 | Equity | 4,616 | +431 | 5.12% | $ 2.849M |
| UnitedHealth Group Inc | UNH US91324P1021 | Equity | 7,195 | +36 | 5.04% | $ 2.802M |
| Novo Nordisk A/S | NOVOB DK0062498333 | Equity | 58,624 | −831 | 4.79% | $ 2.664M |
| Merck & Co Inc | MRK US58933Y1055 | Equity | 16,233 | −2,439 | 4.31% | $ 2.399M |
| Johnson & Johnson | JNJ US4781601046 | Equity | 8,166 | −108 | 3.90% | $ 2.171M |
|
Roche Holding AG
|
RHHBY US7711951043 | Equity | 38,978 | −5,560 | 3.76% | $ 2.093M |
| Revolution Medicines Inc | RVMD US76155X1000 | Equity | 9,951 | −1,020 | 3.68% | $ 2.046M |
| Cytokinetics Inc | CYTK US23282W6057 | Equity | 27,649 | +10,580 | 3.53% | $ 1.961M |
| Bridgebio Pharma Inc | BBIO US10806X1028 | Equity | 23,113 | +2,786 | 3.18% | $ 1.77M |
| Gilead Sciences Inc | GILD US3755581036 | Equity | 11,884 | −1,377 | 3.13% | $ 1.739M |
| Abbott Laboratories | ABT US0028241000 | Equity | 15,601 | −208 | 3.10% | $ 1.722M |
| Vertex Pharmaceuticals Inc | VRTX US92532F1003 | Equity | 3,079 | −319 | 3.02% | $ 1.677M |
| Danaher Corp | DHR US2358511028 | Equity | 7,756 | +199 | 2.98% | $ 1.656M |
| AstraZeneca PLC | AZN GB0009895292 | Equity | 9,969 | −1,209 | 2.91% | $ 1.617M |
|
Novartis AG
|
NOVN CH0012005267 | Equity | 10,564 | −1,063 | 2.90% | $ 1.611M |
| AbbVie Inc | ABBV US00287Y1091 | Equity | 5,088 | −626 | 2.35% | $ 1.305M |
| Bristol-Myers Squibb Co | BMY US1101221083 | Equity | 18,719 | −220 | 2.25% | $ 1.251M |
| Kodiak Sciences Inc | KOD US50015M1099 | Equity | 33,234 | new +33,234 | 2.23% | $ 1.241M |
| Intuitive Surgical Inc | ISRG US46120E6023 | Equity | 3,200 | +1,610 | 2.17% | $ 1.206M |
| Medtronic PLC | MDT IE00BTN1Y115 | Equity | 13,029 | −174 | 2.12% | $ 1.181M |
| McKesson Corp | MCK US58155Q1031 | Equity | 1,182 | −14 | 1.88% | $ 1.046M |
| Dexcom Inc | DXCM US2521311074 | Equity | 11,085 | −2,427 | 1.82% | $ 1.009M |
| Amgen Inc | AMGN US0311621009 | Equity | 1,901 | −1,045 | 1.47% | $ 817.202K |
| Madrigal Pharmaceuticals Inc | MDGL US5588681057 | Equity | 1,499 | −20 | 1.46% | $ 809.505K |
| Edwards Lifesciences Corp | EW US28176E1082 | Equity | 8,572 | −1,916 | 1.40% | $ 777.909K |
| Regeneron Pharmaceuticals Inc | REGN US75886F1075 | Equity | 929 | −479 | 1.34% | $ 742.345K |
| Stryker Corp | SYK US8636671013 | Equity | 2,284 | new +2,284 | 1.33% | $ 739.559K |
| Boston Scientific Corp | BSX US1011371077 | Equity | 15,214 | −71 | 1.32% | $ 734.836K |
| Alnylam Pharmaceuticals Inc | ALNY US02043Q1076 | Equity | 2,566 | +612 | 1.11% | $ 617.611K |
| Teva Pharmaceutical Industries | TEVA US8816242098 | Equity | 16,554 | −13,719 | 1.07% | $ 596.772K |
| Chugai Pharmaceutical Co Ltd | 4519 JP3519400000 | Equity | 13,731 | −184 | 1.07% | $ 594.193K |
| Xenon Pharmaceuticals Inc | XENE CA98420N1050 | Equity | 8,283 | −110 | 0.90% | $ 498.802K |
| Arrowhead Pharmaceuticals Inc | ARWR US04280A1007 | Equity | 5,263 | −1,977 | 0.78% | $ 433.619K |
| Scholar Rock Holding Corp | SRRK US80706P1030 | Equity | 6,177 | −3,470 | 0.63% | $ 350.854K |
| Stoke Therapeutics Inc | STOK US86150R1077 | Equity | 9,917 | −132 | 0.56% | $ 309.41K |
| MBX Biosciences Inc | MBX US55287L1017 | Equity | 5,010 | −3,751 | 0.56% | $ 308.616K |
| Viking Therapeutics Inc | VKTX US92686J1060 | Equity | 8,426 | −112 | 0.50% | $ 276.204K |
| Insulet Corp | PODD US45784P1012 | Equity | 1,827 | −1,008 | 0.49% | $ 271.602K |
| Gubra A/S | GUBRA DK0062266474 | Equity | 4,429 | −58 | 0.47% | $ 261.11K |
| Insmed Inc | INSM US4576693075 | Equity | 2,038 | −1,411 | 0.45% | $ 248.269K |
| Zealand Pharma A/S | ZEAL DK0060257814 | Equity | 5,223 | −70 | 0.44% | $ 243.479K |
| Kailera Therapeutics Inc | KLRA US4829311020 | Equity | 14,039 | new +14,039 | 0.39% | $ 216.201K |
|
First American Treasury Obliga
|
FXFXX US31846V3289 | Money market | 195,957.05 | −177,539.65 | 0.35% | $ 195.957K |
| Intellia Therapeutics Inc | NTLA US45826J1051 | Equity | 13,708 | −184 | 0.31% | $ 174.503K |
| Ionis Pharmaceuticals Inc | IONS US4622221004 | Equity | 2,427 | −3,172 | 0.26% | $ 146.494K |